Market open
Agios/$AGIO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Ticker
$AGIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
385
Website
Agios Metrics
BasicAdvanced
$1.9B
Market cap
2.83
P/E ratio
$11.80
EPS
0.75
Beta
-
Dividend rate
Price and volume
Market cap
$1.9B
Beta
0.75
52-week high
$59.29
52-week low
$20.96
Average daily volume
957K
Financial strength
Current ratio
8.993
Quick ratio
8.438
Long term debt to equity
2.737
Total debt to equity
3.74
Management effectiveness
Return on assets (TTM)
-18.17%
Return on equity (TTM)
53.65%
Valuation
Price to earnings (TTM)
2.831
Price to revenue (TTM)
57.423
Price to book
1.17
Price to tangible book (TTM)
1.17
Price to free cash flow (TTM)
-5.718
Growth
Revenue change (TTM)
36.79%
Earnings per share change (TTM)
-397.66%
3-year earnings per share growth (CAGR)
-22.09%
What the Analysts think about Agios
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Agios stock.
Agios Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Agios Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Agios News
AllArticlesVideos
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
GlobeNewsWire·2 weeks ago
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
GlobeNewsWire·3 weeks ago
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Agios stock?
Agios (AGIO) has a market cap of $1.9B as of December 30, 2024.
What is the P/E ratio for Agios stock?
The price to earnings (P/E) ratio for Agios (AGIO) stock is 2.83 as of December 30, 2024.
Does Agios stock pay dividends?
No, Agios (AGIO) stock does not pay dividends to its shareholders as of December 30, 2024.
When is the next Agios dividend payment date?
Agios (AGIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Agios?
Agios (AGIO) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.